Given CAV1’s role in both tumour cells and stroma, therapeutic targeting of CAV1 in HCC may have dual benefits: inhibiting cancer cells while modulating the pro-carcinogenic microenvironment, potentially sensitising tumour cells to immunotherapy. Here, CAV1 is linked to hepatocellular carcinoma.